Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BGM0504 Tablets Under Different Dosing Conditions in Healthy Chinese Participants
NCT07566572Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BGM0504 in obesity and type 2 diabetes mellitus (T2DM), sponsored by BrightGene Bio-Medical Technology. Primary endpoints: Area Under the Concentration-Time Curve During a Dosing Interval at Steady State at 4 weeks, Maximum Observed Plasma Concentration at Steady State at 4 weeks and 1 more. Started Mar 2026; status: completed.
02
Drugs
BGM0504
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07566572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07566572.